Effects of Digoxin on Morbidity and Mortality in Diastolic Heart Failure | Zendy

Ali Ahmed | Zendy; Michael W. Rich | Zendy; Jerome L. Fleg | Zendy; Michael R. Zile | Zendy; James B. Young | Zendy; Dalane W. Kitzman | Zendy; Thomas E. Love | Zendy; Wilbert S. Aronow | Zendy; Kirkwood F. Adams | Zendy; Mihai Gheorghiade | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effects of Digoxin on Morbidity and Mortality in Diastolic Heart Failure

Author(s) -

Ali Ahmed,

Michael W. Rich,

Jerome L. Fleg,

Michael R. Zile,

James B. Young,

Dalane W. Kitzman,

Thomas E. Love,

Wilbert S. Aronow,

Kirkwood F. Adams,

Mihai Gheorghiade

Publication year - 2006

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.106.628347

Subject(s) - medicine , digoxin , heart failure , ejection fraction , hazard ratio , cardiology , diastolic heart failure , ambulatory , sinus rhythm , diastole , placebo , digitalis , confidence interval , atrial fibrillation , blood pressure , alternative medicine , pathology

About half of the 5 million heart failure patients in the United States have diastolic heart failure (clinical heart failure with normal or near-normal ejection fraction). Except for candesartan, no drugs have been tested in randomized clinical trials in these patients. Although digoxin was tested in an appreciable number of diastolic heart failure patients in the Digitalis Investigation Group ancillary trial, detailed findings from this important study have not previously been published.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research